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Abstract
Juvenile idiopathic arthritis (JIA), as a chronic condition, is associated with significant disease- and treatment-related
morbidity, thus impacting children’s quality of life. In order to optimize JIA management, the paediatric rheumatologist
has begun to regularly use measurements of disease activity developed, validated and endorsed by international
paediatric rheumatology professional societies in an effort to monitor the disease course over time and assess the
efficacy of therapeutic interventions in JIA patients.
A literature review was performed to describe the main outcome measures currently used in JIA patients to determine
disease activity status.
The Juvenile Disease Activity Score (JADAS), in its different versions (classic JADAS, JADAS-CRP and cJADAS) and the
validated definitions of disease activity and response to treatment represent an important tool for the assessment of
clinically relevant changes in disease activity, leading more and more to a treat-to-target strategy, based on a tight and
thorough control of the patient condition. Moreover, in recent years, increasing attention on the incorporation of
patient-reported or parent-reported outcomes (PRCOs), when measuring the health state of patients with paediatric
rheumatic diseases has emerged.
We think that the care of JIA patients cannot be possible without taking into account clinical outcome measures and,
in this regard, further work is required.
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Background
Juvenile idiopathic arthritis (JIA) is a chronic disease
characterized by prolonged synovial inflammation that
may cause structural joint damage [1]. Nonreversible ab-
normalities may also occur in extra-articular organs,
such as the eye (as a complication of iridocyclitis) or the
kidney (due to systemic amyloidosis), or may result from
adverse effects of drug therapies [2]. This morbidity may
impair the quality of life of patients and their families [3].
The objectives of the management of JIA are to ameli-
orate patient symptoms and to improve inflammatory
manifestations in an effort to improve health-related
quality of life (HRQL) and prevent irreversible damage.
The attainment of these goals is facilitated by the con-
stant monitoring of disease course and child health
status through the regular application of validated out-
come measures [4, 5]. The incorporation of these assess-
ments in daily care requires the use of simple and
feasible tools, that are easily utilizable in a busy clinic.
In the past few years, numerous outcome measures
have been developed and validated for use in children
which JIA, including methods for scoring disease activity
and disease damage, therapeutic response criteria, and
questionnaires for the estimation of physical functioning
and HRQL (reviewed in [6, 7]). Most recently, there has
been an increased focus on parent- and child-reported
outcomes (PCROs) [6, 8–10]. These instruments are
considered valuable as they capture the parent and child
perception of disease state and results of treatment. It is
now agreed that the inclusion of PCROs in clinical prac-
tice may lead to improve the quality of care [11].
This review is aimed to provide an update on current
research in outcome assessment in JIA, with special
focus on physician centered disease activity measures.
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Disease activity
The regular measurement of disease activity level is es-
sential to monitor the disease course over time in chil-
dren with JIA and allows the assessment of the efficacy
of therapeutic interventions [12, 13]. However, it is
widely agreed that no single measure can reliably cap-
ture overall disease activity in all JIA phenotypes. There-
fore, the use of the so-called composite disease activity
scores has markedly increased in the last decade. These
tools are made up by pooling several individual mea-
sures in a single instrument and have the advantage of
integrating multiple aspects of the disease into one sum-
mary number on a continuous scale [14]. Composite
scores are ideally suited for the assessment of disease ac-
tivity in single patients, therapeutic efficacy in clinical
trials, and to compare disease status between patients or
patient groups.
The juvenile arthritis disease activity score
In 2009, our group developed the first composite disease
activity score for JIA, named Juvenile Arthritis Disease
Activity Score (JADAS) [15]. The JADAS includes the
following four measures: physician’s global assessment of
disease activity, measured on a 0–10 visual analog scale
(VAS) where 0 = no activity and 10 =maximum activity;
parent global assessment of well-being, measured on a
0-10 VAS where 0 = very well and 10 = very poor; the
erythrocyte sedimentation rate (ESR), normalized to a 0
to 10 scale; and a count of joints with active disease
(Table 1).
In the process of developing the JADAS, it was felt
that the score components should have been selected
among the six variables included in the ACR Pediatric
core set [16]. However, two of the six variables included
in the core set, namely restricted joint count and phys-
ical function assessment, were not included in the
JADAS because they were considered to be relevantly af-
fected by functional or structural damage [17]. It was
deemed important to include parent global assess-
ment, in order to incorporate parents’ perception of
disease activity, even though this measure was also
found to reflect functional damage, particularly in the
later stages of illness [17].
Parent global assessment of well-being and physician’s
global assessment of disease activity can be both assessed
on a linear 10 cm VAS and in a 21-circle VAS [18].
Three versions of the JADAS were developed, each
one differing in the active joint count incorporated:
JADAS10, JADAS27 and JADAS71. The JADAS10 is
based on the count of any involved joint, irrespective of
its type, up to a maximum of ten joints: any joint count
higher than ten yields ten points in the score. The
JADAS27 includes a selected count of the following
joints: cervical spine, elbows, wrists, metacarpophalan-
geal joints (from first to third), proximal interphalangeal
joints, hips, knees and ankles. This is based on previous
analysis that showed that the 27-joint reduced count is a
good surrogate for the whole joint count in JIA [19].
The active joint count included in the JADAS71 was
meant to be unrestricted. However, this version of the
score was developed and validated using a rheumatologic
examination form that included 71 joints [19]. It is im-
portant to remark that this form does not include the
thoracic and lumbar spine, currently included in the










• JADAS10 0–10-cm VAS 0–10-cm VAS Simple count, 0–10a Normalized ESR (0–10)c 0–40
• JADAS27 0–10-cm VAS 0–10-cm VAS Reduced count, 0–27 Normalized ESR (0–10)c 0–57
• JADAS71 0–10-cm VAS 0–10-cm VAS Simple count, 0–71 Normalized ESR (0–10)c 0–101
JADAS-CRP
• JADAS10-CRP 0–10-cm VAS 0–10-cm VAS Simple count, 0–10a Normalized CRP (0–10)b 0–40
• JADAS27-CRP 0–10-cm VAS 0–10-cm VAS Reduced count, 0–27 Normalized CRP (0–10)b 0–57
• JADAS71-CRP 0–10-cm VAS 0–10-cm VAS Simple count, 0–71 Normalized CRP (0–10)b 0–101
cJADAS
• cJADAS-10 0–10-cm VAS 0–10-cm VAS Simple count, 0–10a – 0–30
• cJADAS-27 0–10-cm VAS 0–10-cm VAS Reduced count, 0–27 – 0–47
• cJADAS-71 0–10-cm VAS 0–10-cm VAS Simple count, 0–71 – 0–91
aWith a cutoff at ten, i.e., any active joint count higher than ten is given ten points
bThe C-reactive protein CRP was truncated to a 0–10 scale according to the following formula: (CRP (mg/l) − 10)/10, similar to the normalized ESR used in the
original JADAS. CRP values <10 mg/l are given 0 points and CRP values >110 mg/l are given ten points
cThe ESR value is normalized to a 0–10 scale according to the following formula: (ESR (mm/h) – 20)/10. ESR values < 20 mm/h are given 0 points and ESR values > 120 m/h
are given ten points
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standard rheumatologic examination adopted by the
Paediatric Rheumatology International Trials Organization
(PRINTO) and by the Pediatric Rheumatology Collabora-
tive Study Group (PRCSG). To solve this formal incongru-
ence, in clinical trials it is advised to combine cervical,
thoracic and lumbar spine in a single joint. Notably, the
sacro-iliac joints are not included in the active joint count
since they cannot be clinically swollen nor do they present
a limited range of motion.
The JADAS is calculated as the simple sum of the
scores of its four components, which yields a global
score of 0–40 for the JADAS10, 0–57 for the JADAS27,
and 0–101 for JADAS71. The instrument is feasible and
possesses both face and content validity. Furthermore, in
the validation analysis, it has exhibited good construct
validity, discriminant validity, and responsiveness to clin-
ically important changes in a large patients’ dataset.
The JADAS-CRP
Recently, Nordal et al. developed and validated an alterna-
tive version of the JADAS by substituting the ESR with
the CRP [20]. JADAS-CRP was calculated similarly to the
original JADAS as the simple sum of its four components,
yielding a global score of 0–40, 0–57 and 0–101 depend-
ing on the joint count used for the JADAS10-CRP,
JADAS27-CRP and JADAS71-CRP, respectively. JADAS-
CRP versions were validated by showing their high correl-
ation (r = 0.99) with the corresponding version of the
original JADAS.
The cJADAS
Recently, McErlane et al. have tested a clinical three-
item version of the score, which excluded the ESR [21].
The modified score was named JADAS3-10, -27, -71, ac-
cording to the active joint count included. However, we
have suggested that the acronym cJADAS, i.e., clinical
JADAS, is preferable in order to avoid any confusion
due to the proximity of numbers [22]. The idea of devel-
oping a clinical version of the score was based on the
notion that ESR and CRP are not routinely measured in
all clinical settings, and therefore the JADAS versions in-
cluding an acute phase reactant could be less feasible.
The cJADAS correlated well with the original JADAS.
The juvenile spondyloarthritis disease activity index
In 2014, Weiss et al. developed and validated the Juven-
ile Spondyloarthritis Disease Activity Index (JSpADA), a
composite disease activity index for children and adoles-
cents with juvenile spondyloarthropathy [23]. The index
development was based on a modified Delphi consensus
survey among a group of 106 international experts,
who were asked to evaluate and rank a series of clinical
and laboratory features as well as parent/patient-
reported and physician-centered outcome measures.
Items with a minimum 80 % consensus among raters
were retained in the score. The following ten items were
finally selected: arthritis, enthesitis, patient pain rating,
acute phase reactants, morning stiffness, clinical sacroi-
liitis, uveitis, and back mobility. The final version of the
JSpADA consists of eight items, each of which is given
the same importance (value = 1). The range of possible
score is, then, 0–8, with higher scores indicating greater
disease activity.
Validation was carried out in a retrospective multicen-
ter cohort of 178 children with newly diagnosed juvenile
spondyloarthritis followed longitudinally. Three key do-
mains that explained 58 % of the variance were identi-
fied by factor analysis: peripheral disease, axial disease,
and uveitis. The instrument demonstrated moderate-to-
high correlation with other established outcome measures,
distinguished well between patients with active and in-
active disease, and proved responsiveness to change in dis-
ease activity over time. Overall, the tool was found to be
quick and easy to complete.
Disease activity states and response to treatment
Inactive disease, low and high disease activity according to
the JADAS
The composite scores are perfectly designed to follow
over time the disease course of a child with JIA. How-
ever, the utility of these tools is greatly enhanced by the
availability of criteria for identifying high and low levels
of activity [24]. Table 2 shows cutoff values in the
JADAS that correspond to the states of inactive disease,
low disease activity, moderate disease activity and high
disease activity. Cutoffs were developed for all JIA sub-
types together and for oligoarticular and polyarticular
JIA separately. Cutoffs for the parent/child acceptable
symptom state were also developed, based on the sub-
jective rating of the parent or the patients, reported in
the Juvenile Arthritis Multidimensional Assessment Re-
port (JAMAR) [25]. The cut-points were developed for




Inactive disease ≤1 ≤1 ≤1
Low disease activity 1.1 – 2 1.1 – 2 1.1 – 1.5
Moderate disease activity 2.1 – 4.2 2.1 – 4.2 1.51 – 4
High disease activity >4.2 >4.2 >4
Polyarthritis
Inactive disease ≤1 ≤1 ≤1
Low disease activity 1.1 – 3.8 1.1 – 3.8 1.1 – 2.5
Moderate disease activity 3.9 – 10.5 3.9 – 8.5 2.51 – 8.5
High disease activity >10.5 >8.5 >8.5
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all the original JADAS versions [26, 27] and for the cJA-
DAS10 [22]. In the original studies, the term “minimal
disease activity” was adopted; however, for sake of uni-
formity with adult rheumatology nomenclature, it was
substituted with “low disease activity”. It is important to
note that patients with systemic JIA and active systemic
features were excluded from those studies, and disease
activity cutoffs for this JIA category are still to be
developed.
Definition of inactive disease, remission, and minimal
disease activity
A different approach to define the different disease activ-
ity states in JIA is based on the use of a core set of
multiple criteria. With this approach, Wallace and co-
workers in 2004 developed the preliminary criteria for
disease remission in JIA through an international collab-
orative effort [28]. Based on these criteria, a patient is
classified as having inactive disease when he/she has no
joints with active disease, no systemic manifestations at-
tributable to JIA, no active uveitis, normal values of
acute phase reactants and a physician global assessment
of disease activity indicating no disease activity. When
the criteria for inactive disease are met for a minimum
of six consecutive months while the patient is receiving
anti-rheumatic medications, the patient is classified as
being in the state of clinical remission with medication.
When the criteria for inactive disease are met for a mini-
mum of 12 consecutive months after the patient has dis-
continued all anti-rheumatic medications, the patient is
classified as being in the state of clinical remission with-
out medication. These criteria have recently been modi-
fied by providing a specific definition for uveitis and
abnormal ESR and by including among the requirements
for achieving the state of inactive disease the duration of
morning stiffness of ≤15 min [29] (Table 3).
A more achievable goal for patients with JIA is the
state of minimal disease activity. It was defined by
Magni-Manzoni and co-workers in 2008 as the presence
of a physician’s global rating of disease activity ≤3.4, a
parent’s global rating of well-being ≤2.5 and a swollen
joint count ≤1 in polyarthritis, and as a physician’s global
assessment of disease activity ≤2.5 and a swollen joint
count = 0 in oligoarthritis [30].
Measures of response to treatment
The most widely accepted criteria to define an improve-
ment in patient disease course in response to a therapeutic
intervention are the American College of Rheumatology
(ACR) Pediatric response criteria developed in 1997 [16].
This criteria are based on the ACR core outcome variables
for juvenile arthritis, namely physician global assessment
of disease activity (10-cm VAS), parent/patient assessment
of overall well-being (10-cm VAS), functional ability, num-
ber of joints with active arthritis (defined as joint effusion
or limitation of motion accompanied by heat, pain, or ten-
derness), number of joints with limited ROM, and ESR.
An ACR Pedi 30 response is defined as at least a 30 % im-
provement from baseline in three of six variables, with no
more than one remaining variable worsening by >30 %.
Similarly, the ACR Pedi 50, 70, 90, and 100 response defi-
nitions require 50 %, 70 %, 90 %, and 100 % improvement,
respectively, in at least three core set variables without
worsening of more than one variable by >30 %. Symmet-
rically, flare is defined as worsening of two variables by at
least 40 % without improvement in more than one vari-
able by 30 % [31]. Soon after their publication, these cri-
teria became the gold standard for the assessment of
response to therapy in JIA. The ACR Pedi 30 criteria are
accepted by both the US Food and Drug Administration
and the European Medicines Agency for all phase III trials
in JIA seeking drug registration [32]. Recently, the ACR
Pediatric 30 was adapted for use in clinical trials in sys-
temic JIA, by adding, besides the six core set variables, the
demonstration of the absence of spiking fever (>38 °C)
during the week preceding the evaluation [33, 34].
Recently, Horneff and co-workers have presented a
definition of improvement based on the JADAS10 [35].
The cutoffs for improvement are different according to
the level of disease activity at baseline. The absolute
changes of the JADAS10, that correspond to a meaning-
ful improvement according to this definition, in patient
being in low, moderate or high disease activity at base-
line, are 4, 10, and 17, whereas the percent changes are
41 %, 53 % and 57 %, respectively. According to the val-
idation analysis in the study, the performance of the
ACR criteria was inferior to that of the JADAS10 im-
provement [35]. The ACR Pediatric response criteria
highlight a change in disease state and are an important
tool for assessment of clinically relevant improvement in
Table 3 Criteria for defining clinical inactive disease in
oligoarticular (persistent and extended), polyarticular (RF+ and -),
and systemic JIA*
Inactive disease
- No joints with active arthritis
- No fever, rash, serositis, splenomegaly, or generalized lymphadenopathy
attributable to JIA
- No active uveitis as defined by the SUN Working Group [28]
- ESR or CRP level within normal limits in the laboratory where tested or,
if elevated, not attributable to JIA
- Physician’s global assessment of disease activity score of best possible
on the scale used
- Duration of morning stiffness of 15 min
JIA juvenile idiopathic arthritis, RF rheumatoid factor, ESR erythrocyte sedimentation
rate, CRP C-reactive protein
*Wallace [29]
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disease activity. They are, therefore, ideally suited to be
used in clinical trials that evaluate the efficacy of a new
therapy in comparison to another therapy or a placebo.
However, the nature of their calculation does not enable
the measurement of patients’ actual disease activity at
the beginning or end of a clinical trial or the comparison
of one patient’s absolute response with that of another
patient. Moreover, such a definition implies that achiev-
ing improvement or flare is dependent on the patient’s
status at baseline, and therefore the absolute level of dis-
ease activity may be different for each patient even
though they meet the same criteria for improvement or
flare [36].
Toward a treat-to-target strategy
In the past 20 years the shift towards early aggressive in-
terventions, the development of new therapeutic agents
including methotrexate and biological medications and
combination treatment strategies have radically changed
the management of JIA patients and improved the long
term outcome [37–39]. This progress has made the at-
tainment of disease remission or, at least, minimal levels
of disease activity, an achievable goal and the therapeutic
aims and patients’ expectations were shifted towards an
inactive disease status [40–42]. Complete disease quies-
cence is regarded as the ideal therapeutic target because
its achievement was demonstrated to prevent further
joint damage and disability, and may improve physical
function and quality of life [43]. Both JADAS-based and
definition-based criteria for inactive disease can be con-
sidered optimal target for a therapeutic intervention in
JIA [44].
The current definition of inactive disease requires the
total absence of any sign or symptom of disease activity
and is, therefore, extremely strict. Even meeting the
JADAS cutoffs for remission is challenging, being the re-
quired score ≤1 for all JADAS versions and for both oli-
goarthritis and polyarthritis. However, achievement of a
real inactive disease either in everyday clinical practice
or in pharmaceutical trials is still problematic in many
patients, particularly those with polyarticular or systemic
JIA. It has been proposed that in clinical care a more at-
tainable goal could be to induce and maintain at least a
state of minimal (or low) disease activity, which is an
intermediate state between high disease activity and re-
mission, though very close to remission [30]. In adult pa-
tients with rheumatoid athritis (RA), this state is deemed
to be a useful target of treatment by both the physician
and the patient, given current treatment possibility and
limitations [45].
Studies in adult patients with (RA) have demonstrated
that clinical and biological outcomes are improved if a
treat to target strategy is implemented, i.e., through the
practice to aim for minimal levels of disease activity by
frequent adjustment of therapy according to quantitative
indices [46–48]. Indeed, the strategy of tight control,
aiming at remission, has been considered more import-
ant than the therapeutic agent [49]. A similar approach
has not yet been reported for JIA; however, the achieve-
ment of the state of inactive disease, at least once in the
first five years of the disease, was found to be associated
with lower levels of long-term damage and lower func-
tional impairment in children with polyarthritis [43]. In
addition, a greater magnitude of clinical response in the
first six months of methotrexate therapy was found to
predict a more favorable long-term outcome [50].
Parent/patient reported outcomes
In recent years, increasing attention has been paid to
PCROs in JIA [8]. Incorporation of these measures in
patient assessment is deemed important as they re-
flect the parents’ and children’s perception of the
disease course and effectiveness of therapeutic inter-
ventions. Information obtained with parent or child
centered measures may contribute significantly to
medical decision-making and increase the probabilities
of success in patient care. Indeed, since physician’s
therapeutic decisions are of primary importance to
parents and patients, integration of their perspective
in clinical evaluation may facilitate concordance with
physician’s choices and compliance with therapeutic
prescriptions [11, 51, 52]. In the chronic phase of the
disease, patients or parents might report high per-
ceived disease activity, high pain levels, high fatigue
and low health-related quality of life (HRQOL) irre-
spective of current active disease. These measures
should lead to support the patient in his/her per-
ceived impaired health status other than to the ad-
justment of medication (except in case of side effects)
and could help the physician to recognize the patients
at risk for impaired perceived health in its broadest
way.
A wide variety of measures for the assessment of
PCRO in children with JIA is currently available, ran-
ging from VAS for rating of child’s overall well-being
and intensity of pain, to questionnaires for the evalu-
ation of functional ability and HRQOL [18, 53–59]. The
issue of drug tolerance has also been recently ad-
dressed, through the development of a methotrexate in-
tolerance score [60]. However, valuable insights into the
influence of the disease and its treatment on the child
and his family may be provided by other PCRO not ad-
dressed by conventional instruments, such as evaluation
of morning stiffness and overall level of disease activity,
rating of disease status and course, proxy- or self-
assessment of joint involvement and extraarticular
symptoms, and assessment of therapeutic compliance
and satisfaction with the outcome of the illness. The
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JAMAR is a recently developed clinical tool that groups
all the main PCROs for children with JIA [25]. The
JAMAR provides the attending physician with a thor-
ough and systematic overview of the patient status to
be scanned briefly at the start of the visit. This ap-
proach facilitates the focus on issues that require atten-
tion, leading to more efficient and effective clinical care
and including valuable insights into the influence of the
disease and its treatment. However, the JAMAR, in
spite of its multidimensional nature, does not explore
some relevant domains, e.g., fatigue or the impact of
the disease in work-related issues.
Currently, a clinical instrument that groups all PCROs
used in the assessment of children with JIA does not
exist.
The American National Institute of Health has created
a cooperative network of researchers to develop new
PCRO scales using modern measurement theory, the
Patient-Reported Outcomes Measurement Information
System (PROMIS) [61]. This initiative is aimed to replace
the multiplicity of disease-specific scales with generic as-
sessment tools that can be used across medical condi-
tions, including juvenile arthritis [62]. The PROMIS
measurement tools are systematically developed using
both qualitative and psychometric methodologies, includ-
ing item response theory, to create either static short
forms or computerized adaptive versions that can be ad-
ministered in an array of clinical and research settings
[63]. Validated PROMIS measures are currently being in-
vestigated for use in patient chronic pain conditions in-
cluding JIA [64].
Finally, composite disease activity scores for JIA en-
tirely based on parent- or child reported outcome mea-
sures were recently developed [65]. The Juvenile
Arthritis Parent Assessment Index (JAPAI) and the Ju-
venile Arthritis Child Assessment Index (JACAI) are
composed of the following items: 1) parent/child rating
of overall well-being on a 0–10 cm VAS (0 = best; 10 =
worst); 2) parent/child rating of pain intensity on a 0–
10 cm VAS (0 = no pain; 10 = very severe pain); 3)
assessment of physical function; 4) assessment of HRQL
(excluded in a three-item version of the scores). Scores
of physical function and HRQL tools included in the
composite scores are converted to a 0–10 score by spe-
cific formulae, yielding a global score of 0–40 for the
four-item versions and of 0–30 for the three-item ver-
sions. The JAPAI and the JACAI demonstrated to be
valid instruments for the assessment of disease status in
JIA and to monitor disease activity over time.
Damage
Prolonged synovial inflammation characterizes the clin-
ical picture of JIA: this, if not properly treated, may
cause irreversible alterations in joint structures. The
involvement of extraarticular organs/systems, such as
the eye (as a complication of chronic anterior uveitis) or
the kidney (due to systemic amyloidosis), may lead to
permanent changes. Moreover, the side effects due to
the prolonged administration of medications may also
cause permanent or long-lasting damage [1].
Morbidity in JIA patients can be evaluated in terms of
functional disability or by assessing structural joint dam-
age through radiographs or other imaging modalities.
However, these tools may not capture the multiple forms
of damage that children with JIA may develop over time,
such as micrognathia, height retardation, localized
growth disturbances, pubertal delay, or visceral organ
failure [66]. The Juvenile Arthritis Damage Index (JADI)
is a clinical tool that enables a thorough detection of ar-
ticular and extra-articular damage in children with JIA
[2], through a simple, easy and quick score which takes
just 5–15 min in the daily clinical setting. The informa-
tion obtained by physical examination and from the
patient’s clinical history is sufficient to complete the
questionnaire and no radiographic examinations are re-
quired. The JADI is aimed to capture damage, defined as
persistent changes in anatomy, physiology, pathology or
function, present for at least six months, which may be
the consequence of previous active disease, side effects
of therapy, or comorbid conditions, and is not due to
currently active arthritis. The index is composed of two
parts, one devoted to the assessment of articular damage
(JADI-A) and one devoted to the assessment of extra-
articular damage (JADI-E). The maximum total score is
72 for JADI-A and 17 for JADI-E. Damage is often irre-
versible and cumulative and, thus, damage scores are ex-
pected to remain stable over time or to increase.
However, because some forms of damage may improve
or even resolve in growing children, in some cases the
total score may decrease.
Conclusions
In the past decade, an intense research effort has been
made to design and validate new outcome measures for the
clinical assessment of children with JIA. The proposed in-
struments have expanded the health domains that can be
evaluated quantitatively. This progress may promote the
regular administration of parent/child questionnaires in
standard clinical care. Although the use of standardized
outcome measure may be facilitated in tertiary care set-
tings, with larger staff assistance, most of the described
measures have been specifically designed for regular admin-
istration in a busy clinical setting, with particular attention
to feasibility and acceptability in daily care. Patient or par-
ent questionnaires can be completed in the waiting area be-
fore the patient is called into an examining room and the
physician should spend only a few seconds reviewing and
scoring the data.
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Furthermore, the use of quantitative measures will in-
crease the reliability of comparison of patient populations
and the analysis of the effectiveness of current and novel
therapeutic protocols. To achieve these goals, the available
tools or those that will be developed in the future should
be tested in patients seen in different geographic areas
and embraced by pediatric rheumatologists practicing in
diverse countries and continents. A potential caveat is that
most outcome measures described in this review have
been developed and validated for use in children and ado-
lescents. To foster harmonization with the assessments
made in young adults in the context of transition of care,
there is a need to adapt the new instruments for use in
the adult age and to scrutinize their correlation with the
existing adult-oriented tools.
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